SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Sharck Soup

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sharck who started this subject1/7/2002 4:54:13 PM
From: GBT   of 37746
 
PDGM a real sleeper. Interesting stuff.

``Paradigm Genetics is a pioneer in the emerging science of metabolomics, and I am delighted to join them in their efforts,'' said Hood. ``I believe that metabolomics will prove to be a very valuable complement to traditional genomic technologies. It holds great promise in the field of systems biology, with the potential to accelerate and improve the analyses of drug targets, lead compounds and predictive medicine.''

Paradigm has developed a robust, integrated functional genomics and metabolomics platform, along with its proprietary informatics technologies, to deliver high value genomic information to the human health, agriculture and nutrition industries. The company has validated its technology in agriculture through its partnerships with Bayer and Monsanto and is now aggressively entering the field of human health with its proprietary metabolomics technology, MetaVantage(TM), created by Paradigm to address the needs of drug discovery and development companies.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext